DHEA-S Suppression After 1-mg Overnight Dexamethasone Test
Suppression of DHEA-S after a 1-mg overnight dexamethasone test indicates that adrenal androgen secretion remains under ACTH control. [1] Adrenocortical carcinoma is an ACTH-independent malignancy risk. [1] Therefore, DHEA-S suppression with 1 mg overnight dexamethasone is expected to argue against adrenal carcinoma as the source of adrenal androgen excess rather than support it. [1]
Physiologic Basis for DHEA-S Response to Low-Dose Dexamethasone
DHEA-S secretion is stimulated by ACTH-dependent adrenal steroidogenesis. [1] Low-dose dexamethasone suppresses ACTH in patients with hypercortisolism, which reduces ACTH-driven adrenal androgen production. [1]
Evidence for Using Low DHEA-S in the Setting of 1-mg Overnight DST
In adrenal incidentalomas, a diagnostic strategy using DHEA-S (as a marker of adrenal androgen output) showed high sensitivity and specificity for identifying subclinical hypercortisolism. [2] In that study population, cortisol after 1 mg overnight dexamethasone suppression testing was used as the core hypercortisolism discriminator, while DHEA-S supported test performance for adrenal functional status. [2]
Adrenocortical Carcinoma Hormonal Evaluation Implications
Guidelines for suspected adrenocortical carcinoma recommend measuring adrenal steroid hormones and androgen precursors such as DHEA-S during the diagnostic work-up. [3] These recommendations address hormone excess characterization rather than a specific expectation that DHEA-S will suppress on low-dose dexamethasone. [3]
Clinical Interpretation Framework for the Specific Scenario
If DHEA-S decreases after a 1-mg overnight dexamethasone test, the pattern supports ACTH dependence of the androgen-secreting pathway. [1] Because ACTH independence is a malignant-risk consideration for adrenal androgen–secreting tumors, DHEA-S suppression after 1 mg overnight dexamethasone is not consistent with adrenal carcinoma as the most likely mechanism for androgen excess. [1]
Key Knowledge Gaps
Direct studies specifically evaluating whether adrenal carcinoma reliably suppresses DHEA-S after a 1-mg overnight dexamethasone test are not established in the cited guideline statements. [1],[3]
Practical Outcome
DHEA-S suppression after 1 mg overnight dexamethasone is clinically interpreted as evidence for ACTH control of adrenal androgen secretion and is therefore more consistent with ACTH-dependent adrenal physiology than with ACTH-independent adrenocortical carcinoma. [1]